Belgium's Fagron FY 2025 revenue grows 9.2%

Fagron NV

12/02/2026 06:07

Overview

Belgium-based pharmaceutical compounding firm reported 9.2% revenue growth for FY 2025

REBITDA increased by 10.9% YoY, supported by operational excellence initiatives

Company completed 12 acquisitions, expanding footprint across all regions

Outlook

Fagron expects mid- to high-single digit organic sales growth in FY 2026

Company anticipates slightly improved margins in FY 2026

Result Drivers

REGIONAL GROWTH - Fagron's growth was supported by strong performance across all regions, particularly in Latin America and North America-Pacific, driven by demand and efficiency initiatives

M&A ACTIVITY - Fagron announced 12 acquisitions, expanding its footprint and capabilities, with integration progressing as planned

OPERATIONAL EXCELLENCE - Operational excellence initiatives and procurement savings supported profitability and cash generation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
EUR 1.25
FY Dividend
EUR 0.40
FY Free Cash Flow
EUR 125.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Fagron NV is €26.00, about 20.4% above its February 11 closing price of €21.60

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nGNE1tqgWf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)